Literature DB >> 21973210

Type 2 diabetes mellitus interacts with obesity and common variations in PLTP to affect plasma phospholipid transfer protein activity.

R P F Dullaart1, M Vergeer, R de Vries, P J W H Kappelle, G M Dallinga-Thie.   

Abstract

BACKGROUND: Phospholipid transfer protein (PLTP) is an emerging cardiometabolic risk marker that is important in high-density lipoprotein (HDL) and triglyceride metabolism. Plasma PLTP activity is elevated in type 2 diabetes mellitus, whereas glucose may regulate PLTP gene transcription in vitro. Of interest, common PLTP variations that predict cardiovascular disease have been identified recently. We investigated whether the diabetic state is able to amplify relationships between obesity and PLTP gene variations with circulating PLTP levels. SUBJECTS AND METHODS: Plasma PLTP activity (using a phospholipid vesicles-HDL system), PLTP gene score [number of PLTP activity-decreasing alleles based on two tagging polymorphisms (rs378114 and rs60- 65904)] and waist circumference were determined in two Dutch cohorts comprising 237 patients with type 2 diabetes and 78 control subjects.
RESULTS: Patients with diabetes were more obese (P < 0.001 for prevalence of increased waist circumference) and had 13% higher plasma PLTP activity (P < 0.001). PLTP gene score was not different in diabetic and control subjects (P = 0.40). PLTP activity was highest in patients with diabetes with an enlarged waist and lowest in control subjects with a normal waist circumference (P < 0.001). Multiple linear regression analysis revealed a positive interaction between diabetes status and waist circumference on PLTP activity (β = 0.200, P = 0.005). Furthermore, diabetes status (β = -0.485, P = 0.046) or HbA1c (β = -0.240, P = 0.035) interacted with PLTP gene score to affect PLTP activity.
CONCLUSIONS: Type 2 diabetes and enlarged waist circumference interact to impact on plasma PLTP activity. Diabetes may also amplify the association between plasma PLTP activity and common PLTP gene variations. Our findings support the hypothesis that diabetes-environment and diabetes-gene interactions govern plasma PLTP activity.
© 2011 The Association for the Publication of the Journal of Internal Medicine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21973210     DOI: 10.1111/j.1365-2796.2011.02465.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  5 in total

1.  Elevated baseline plasma phospholipid protein (PLTP) levels are an independent predictor of long-term all-cause mortality in patients with diabetes mellitus and known or suspected coronary artery disease.

Authors:  Erdal Cavusoglu; Jonathan D Marmur; Sandeep Chhabra; Mohammad R Hojjati; Sunitha Yanamadala; Vineet Chopra; Calvin Eng; Xian-Cheng Jiang
Journal:  Atherosclerosis       Date:  2015-02-16       Impact factor: 5.162

2.  Serum CETP and PLTP activity in middle-aged men living in urban or rural area of the Lower Silesia region. PURE Poland sub-study.

Authors:  Anna Skoczyńska; Anna Wojakowska; Barbara Turczyn; Katarzyna Zatońska; Maria Wołyniec; Andrzej Szuba
Journal:  Arch Med Sci       Date:  2016-07-01       Impact factor: 3.318

3.  Plasma phospholipid transfer protein activity is inversely associated with betaine in diabetic and non-diabetic subjects.

Authors:  R P F Dullaart; Erwin Garcia; Elias Jeyarajah; Eke G Gruppen; Margery A Connelly
Journal:  Lipids Health Dis       Date:  2016-08-31       Impact factor: 3.876

4.  Serum Lipid Transfer Proteins in Hypothyreotic Patients Are Inversely Correlated with Thyroid-Stimulating Hormone (TSH) Levels.

Authors:  Anna Skoczyńska; Anna Wojakowska; Barbara Turczyn; Katarzyna Zatońska; Maria Wołyniec; Natalia Rogala; Andrzej Szuba; Grażyna Bednarek-Tupikowska
Journal:  Med Sci Monit       Date:  2016-11-30

5.  Association between the PLTP rs4810479 SNP and Serum Lipid Traits in the Chinese Maonan and Han Populations.

Authors:  Fen-Han Zhang; Rui-Xing Yin; Li-Mei Yao; Wei-Xiong Lin; Jin-Zhen Wu; De-Zhai Yang
Journal:  Genet Res (Camb)       Date:  2021-07-02       Impact factor: 1.588

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.